An­oth­er sparse round of NASH da­ta; TG rais­es $60M af­ter PhI­II suc­cess

→ The la­bor­ing NASH field added a new but sparse round of da­ta this morn­ing, with Ax­cel­la re­leas­ing re­sults from a small non-IND en­abled study on a pair of drugs. The study ran­dom­ized 102 par­tic­i­pants to place­bo dif­fer­ent dos­es of one of two Ax­cel­la drug can­di­dates, AXA1125 or AXA1957. Of the AXA1957 arm, 39% had a re­duc­tion in liv­er fat of over 30%, com­pared to 8% for the place­bo arm. The re­sults add an­oth­er bit of da­ta for a field that has seen its share of large-scale fail­ures over the last year and is large­ly wait­ing for the much-de­layed Phase III read­out from Gen­fit, which is now ex­pect­ed to come lat­er this month.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER